Kenvue Inc. (KVUE): price, analyst ratings, earnings and fundamentals

Updated 16 September 2026, 08:02 ET

Kenvue Inc. (KVUE) closed at $17.92 on 15 September 2026, up 0.1%. The stock is down 6.7% over one month and down 5.6% over one year. It trades 11.0% below its 52-week high of $20.13. Analysts recorded 3 actions in the last 90 days; the median price target of $19 is 6.0% above the last close. The company last reported on 6 August 2026 for Q2 2026: EPS of $0.31 against an estimate of $0.32, a miss of 3.1%, on revenue of $4.0 billion.

Price and performance

Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.

The live chart with technical indicators is in the app: open KVUE in FundSpec.

Analyst ratings

Over the last 90 days FundSpec recorded 3 analyst actions on KVUE from 2 firms: 3 maintained or reiterated a view. Price targets were 2 raised and 1 lowered. The most recent price target on file, from 3 firms, is $19, 6.0% above the last close.

A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.

Every action with the firm's history is in Analyst Ratings.

Earnings

The next report is scheduled for 2 November 2026 before the open for Q3 2026, with EPS expected at $0.29 on revenue of $3.9 billion. Kenvue Inc. beat the EPS estimate in 6 of its last 7 reported quarters.

An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.

Estimates, confirmed dates and alerts for every company are in Earnings.

Fundamentals

On a trailing twelve month basis the company shows revenue growth of N.A., a gross margin of N.A., an operating margin of N.A. and a return on equity of N.A..

Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.

Fair value, peer multiples and the full statement history are in the app: open KVUE in FundSpec.

SEC filings

The latest filing is a 10-Q from 6 August 2026.

Company profile

Exchange

NYSE

Sector

Manufacturing

Industry

Consumer Goods

Chief executive

Thibaut Mongon

Website

www.jnj.com/kenvue/

SEC CIK

0001944048

We are the world’s largest pure-play consumer health company by revenue with $15.0 billion in net sales in 2022. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Prior to the completion of this offering, we are a wholly owned subsidiary of Johnson & Johnson. Our principal executive offices are located at 199 Grandview Road, Skillman, NJ.

Sector and peers

Kenvue Inc. is part of the Manufacturing sector, which FundSpec tracks across 1 company.